Science 37 Holdings

Science 37 Holdings, Inc. provides technology-based solutions that enables decentralized clinical trials. The company is headquartered in Durham, NC.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

MORRISVILLE, N.C., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Science 37 , a leader in enhancing patient access to clinical trials, today announced the grand opening of its new, 19,000-square-foot corporate headquarters in Morrisville, North Carolina, in the heart of Research Triangle Park.

Science 37 Unveils New Corporate Headquarters in Research Triangle Park, NC

RESEARCH TRIANGLE PARK, N.C., June 27, 2024 (GLOBE NEWSWIRE) -- Science 37 , a leader in enhancing patient access to clinical trials, has been added to over 20 studies that were lagging in recruitment, helping them to trend back towards their projected targets.

Science 37 Quickly Impacts Performance in Under-Enrolling Clinical Trials

RESEARCH TRIANGLE PARK, N.C., June 12, 2024 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Science 37, Inc., please note that the first sentence of the second paragraph has been revised.

CORRECTION-- Science 37 Surpasses Enrollment Goals, Accelerates Phase 2 Rare Disease Clinical Trial

RESEARCH TRIANGLE PARK, N.C., May 13, 2024 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. today announced the preliminary outcome of its recent FDA Inspection focusing on critical areas and documentation.

Science 37 Metasite™ Undergoes Successful FDA Inspection, Marking Major Milestone in Virtual Site Quality Assurance and Compliance

Science 37 announces its selection as the winner of the “Clinical Efficiency Innovation Award” in the 8th annual MedTech Breakthrough Awards program.

Science 37 Wins 2024 MedTech Breakthrough Award for “Clinical Efficiency Innovation”

RESEARCH TRIANGLE PARK, N.C., May 02, 2024 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. today disclosed the latest enrollment figures resulting from its Metasite™ and Patient Recruitment partnership with a leading biotech company whose asthma drug is currently undergoing a Phase 3 clinical trial.

Science 37 Delivers 22x Faster Enrollment than Traditional Methods in Phase 3 Asthma Clinical Trial

RESEARCH TRIANGLE PARK, N.C., April 17, 2024 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc., the clinical research industry's leading MetasiteTM, today announced the launch of a stand-alone Patient Recruitment Solution to deliver patients to sites that are eligible, medically reviewed, and fully consented.

Science 37 Provides Fully Consented Patients to Sites to Supplement Enrollment

MIAMI , March 12, 2024 /PRNewswire/ -- eMed, LLC ("eMed") today announced the successful completion of the previously announced tender offer by its wholly-owned subsidiary, Marlin Merger Sub Corporation ("Purchaser"), for all the outstanding shares of common stock, par value $0.0001 per share, of Science 37 Holdings, Inc. (NASDAQ: SNCE) ("Science 37") at a price of USD 5.75 per share. Continental Stock Transfer & Trust Company, the depositary for the tender offer, has advised Purchaser that, as of 12:00 Midnight, New York City time, at the end of the day of Monday, March 11, 2024 (the "Expiration Time"), the expiration of the tender offer, (i) 4,715,950 shares were validly tendered and not withdrawn in the tender offer, representing approximately 77.8% of Science 37's outstanding shares of common stock, and (ii) notices of guaranteed delivery had been delivered with respect to 76,755 additional shares, representing approximately 1.3% of the outstanding shares.

eMed completes tender offer for all outstanding shares of Science 37

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Science 37 Holdings, Inc. (NasdaqCM: SNCE) to eMed, LLC. Under the terms of the proposed transaction, shareholders of Science 37 will receive $5.75 in cash for each share of Science 37 that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether.

SCIENCE 37 HOLDINGS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Science 37 Holdings, Inc. - SNCE

MIAMI , Feb. 12, 2024 /PRNewswire/ -- eMed, LLC ("eMed") today announced that its wholly-owned subsidiary, Marlin Merger Sub Corporation, a Delaware corporation ("Purchaser"), has commenced a cash tender offer to purchase all the outstanding shares of common stock, par value $0.0001 per share, of Science 37 Holdings, Inc. (NASDAQ: SNCE) ("Science 37") for a price of $5.75 per share (the "Offer"). The Offer is being made upon the terms and subject to the conditions set forth in the Offer to Purchase, dated February 12, 2024 and the related Letter of Transmittal and pursuant to the terms of the previously announced Agreement and Plan of Merger, dated as of January 28, 2024 (the "Merger Agreement"), among eMed, Purchaser and Science 37.

eMed commences tender offer for Science 37

MILWAUKEE , Jan. 31, 2024 /PRNewswire/ -- Ademi LLP is investigating Science 37 (Nasdaq: SNCE) for possible breaches of fiduciary duty and other violations of law in its transaction with eMed. Click here to learn how to join the https://www.ademilaw.com/case/science-37-holdings-inc or call Guri Ademi toll-free at 866-264-3995.

Shareholder Alert: Ademi LLP investigates whether Science 37 Holdings, Inc. has obtained a Fair Price in its transaction with eMed

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Science 37 Holdings, Inc. (NASDAQ: SNCE) to eMed, LLC for $5.75 in cash per share is fair to Science 37 shareholders. Halper Sadeh encourages Science 37 shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Science 3.

SNCE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Science 37 Holdings, Inc. Is Fair to Shareholders

RESEARCH TRIANGLE PARK, N.C., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE) (the “Company” or “Science 37”), the clinical research industry's leading MetasiteTM, today announced that it has entered into a definitive merger agreement to be acquired by eMed, LLC (“eMed”), the leader in on-demand virtual care and treatment for consumers.

Science 37 to be Acquired by eMed, Expanding Access to Patients and Accelerating Enrollment

Science 37 emerges as the only clinical trial site to be recognized as a Leader in Decentralized Clinical Trials Science 37 emerges as the only clinical trial site to be recognized as a Leader in Decentralized Clinical Trials

Science 37 Receives Top Honors in Everest PEAK Matrix®

RESEARCH TRIANGLE PARK, N.C., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the industry-leading Metasite™, today announced the granting of inducement equity awards under the Science 37 Holdings, Inc. Amended and Restated 2022 Employment Inducement Incentive Award Plan (the “Plan”). The Plan was approved by Science 37's Board of Directors in November 2023. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Science 37's Compensation Committee and made as a material inducement to the non-executive employees' entry into employment with the Company.

Science 37 Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE) (“Science 37” or the “Company”), the clinical research industry-leading Metasite™, announced today that it will effect a 1-for-20 reverse stock split (“Reverse Stock Split”) of its outstanding common stock, par value $0.0001 per share (“Common Stock”), that will become effective on December 8, 2023, at 12:01 a.m., Eastern Time. Science 37's Common Stock will continue to trade on The Nasdaq Capital Market (“Nasdaq”) under the existing symbol “SNCE” and will begin trading on a split-adjusted basis when the market opens on December 8, 2023. The new CUSIP number for the Common Stock following the Reverse Stock Split will be 808644207.

Science 37 Holdings, Inc. Announces 1-for-20 Reverse Stock Split effective December 8, 2023

Science 37 Holdings, Inc. (NASDAQ:SNCE ) Q3 2023 Earnings Conference Call November 7, 2023 8:30 AM ET Company Participants Steve Halper - Investor Relations David Coman - Chief Executive Officer Mike Zaranek - Chief Financial Officer Conference Call Participants Charles Rhyee - Cowen and Company Matt Hewitt - Craig-Hallum Christine Rains - William Blair Nelson Cox - Lake Street Operator Greetings and welcome to the Science 37 Third Quarter 2023 Earnings Call. [Operator Instructions] As a reminder, this conference is being recorded.

Science 37 Holdings, Inc. (SNCE) Q3 2023 Earnings Call Transcript

RESEARCH TRIANGLE PARK, N.C., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), (“Science 37”), the industry-leading Metasite™, today reported its financial results for the quarter ended September 30, 2023.

Science 37 Reports Third Quarter 2023 Financial Results

RESEARCH TRIANGLE PARK, N.C., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the industry-leading Metasite™ today announced it will report third quarter 2023 financial results prior to the market open on Tuesday, November 7, 2023.

Science 37 to Report Third Quarter 2023 Financial Results on November 7, 2023

RESEARCH TRIANGLE PARK, N.C., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the clinical research industry-leading Metasite™, today announced that its Chief Delivery Officer, Darcy Forman, has been honored with a coveted spot on the prestigious PharmaVoice 100 list. This recognition not only underscores Darcy's leadership, it highlights the industry-wide impact of Science 37 and its positive contributions to patients, community providers, CROs, and clinical trial sponsors.

Science 37 Chief Delivery Officer, Darcy Forman, Named to Prestigious PharmaVoice 100 List

RESEARCH TRIANGLE PARK, N.C., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Science 37 announced today that it has been recognized in the Gartner Hype Cycle for Life Science Clinical Development, 2023. As stated by Gartner, “This Hype Cycle explores innovative technologies that are specifically relevant to life science clinical development programs in the pharmaceutical, biotechnology, diagnostics, medical device, research institutions, and contract research sectors.”

Science 37 Recognized in the Gartner® Hype Cycle™ for Life Science Clinical Development, 2023

RESEARCH TRIANGLE PARK, N.C., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the clinical research industry-leading Metasite™, today announced that it has been honored with the prestigious Frost & Sullivan Market Leadership Award in the global decentralized clinical trials industry. This acknowledgment highlights Science 37's accomplishments, and solidifies its role as an industry leader, as it continues to transform clinical trial conduct through the Metasite.

Science 37 Named Market Leader for Global Decentralized Clinical Trials by Frost & Sullivan

RESEARCH TRIANGLE PARK, N.C., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the industry-leading Metasite™, today announced the company will be participating in the upcoming H.C. Wainwright 25th Annual Global Investment Conference on Monday, September 11, 2023.

Science 37 to Participate in H.C. Wainwright 25th Annual Global Investment Conference

RESEARCH TRIANGLE PARK, N.C., Aug. 15, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the clinical research industry-leading Metasite™ is proud to announce its nomination for the prestigious 2023 Prix Galien USA Awards in the category of "Best Digital Health Solution.” The Prix Galien Awards, organized by The Galien Foundation, recognize and celebrate groundbreaking innovations in the life sciences industry that significantly advance human health and well-being.

Science 37 Recognized as Best Digital Health Solution Nominee at 2023 Prix Galien USA Awards

Science 37 Holdings, Inc. (NASDAQ:SNCE ) Q2 2023 Results Conference Call August 8, 2023 8:30 AM ET Company Participants Steven Halper - LifeSci Advisors David Coman - CEO Mike Zaranek - CFO Conference Call Participants Frank Takkinen - Lake Street Capital Markets Christine Rains - William Blair Matt Hewitt - Craig-Hallum Capital Group Operator Greetings, and welcome to the Science 37 Second Quarter 2023 Earnings Call. [Operator Instructions] As a reminder, this conference is being recorded.

News for Science 37 Holdings Stock (SNCE)